Janus Henderson Group PLC Eq Rx, Inc. Transaction History

Janus Henderson Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.66 - $2.31 $1 - $2	1 Added 0.0%	72,799 $161,000
Q2 2023 Aug 14, 2023	SELL	$1.61 - $1.96 $1,096 - $1,334	-681 Reduced 0.93%	72,798 $135,000
Q1 2023 May 15, 2023	BUY	$1.8 - $2.83 $62,526 - $98,305	34,737 Added 89.66%	73,479 $142,000
Q4 2022 Feb 14, 2023	SELL	$2.05 - $5.5 $2 - $5	-1 Reduced -0.0%	38,742 $95,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $5.99 $987 - $6,289	-1,050 Reduced 2.64%	38,743 $191,000
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.69 $127,337 - $226,422	39,793 New	39,793 $187,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.